<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="139033">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on April 10, 2017</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01291069</url>
  </required_header>
  <id_info>
    <org_study_id>IRB_00050085</org_study_id>
    <nct_id>NCT01291069</nct_id>
  </id_info>
  <brief_title>Effect of Tadalafil on Exercise Capacity in Pediatric Fontan Patients</brief_title>
  <official_title>Effect of Tadalafil on Exercise Capacity in Pediatric Fontan Patients</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Utah</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Utah</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      This pilot study is aimed at assessing the short-term effects of Tadalafil on the
      hemodynamic response to exercise and exercise capacity in patients with Fontan circulation.
      Data regarding effect size and drug tolerability will be used in the design of a randomized
      multicenter trial. The long-term goal of this investigation is to systematically evaluate
      the effect of tadalafil therapy on exercise performance, quality of life, and delay of
      functional deterioration in patients with single ventricle physiology.
    </textblock>
  </brief_summary>
  <overall_status>Unknown status</overall_status>
  <last_known_status>Recruiting</last_known_status>
  <start_date>September 2011</start_date>
  <primary_completion_date type="Anticipated">February 2013</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Double Blind (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To compare the effects of Tadalafil versus placebo on exercise capacity (maximal oxygen consumption: VO2 max) for patients (8-35 years)with the Fontan circulation (8 -18 years).</measure>
    <time_frame>2 years</time_frame>
    <description>Short-term treatment with Tadalafil will augment cardiac output and improve exercise capacity (maximal oxygen consumption: VO2 max) in patients with the Fontan circulation. Primary outcome variables include the change in peak exercise capacity (VO2 max), using cycle ergometry after one week of tadalafil therapy</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>To evaluate the adverse effects of Tdalafil in patients (8-35 years)with the Fontan circulation and compare with the placebo group.</measure>
    <time_frame>2 years</time_frame>
    <description>Hypothesis: Short-term treatment with Tadalafil will be well tolerated by children with the Fontan circulation. Adverse effect forms will be used to compare the side effects between Tadalafil and treatment group.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">44</enrollment>
  <condition>Single Ventricle</condition>
  <arm_group>
    <arm_group_label>Tadalafil Citrate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>The study subjects will be given Tadalfil citrate, encapsulated, 0.8-1 mg/kg/day in 1 dose orally. Max dose 40 mg. All patients will receive either study drug or placebo for a total of 20 days.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Sugar pill</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>If allocated to the placebo arm, the child will be given a similar appearing medication; the placebo will be a sugar pill. All patients will receive either study drug or placebo for a total of 20 days.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Tadalafil Citrate</intervention_name>
    <description>If allocated to the treatment arm, the patient will be given tadalfil citrate, 0.8-1 mg/kg/day in 1 daily dose. Maximum dose 40 mg. All patients will receive either study drug or placebo for a total of 20 days.</description>
    <arm_group_label>Tadalafil Citrate</arm_group_label>
    <other_name>Cialis</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sugar pill</intervention_name>
    <description>If allocated to the placebo arm, the child will be given a similar appearing medication; the placebo will be a mixture of Ora-Sweet® and Ora-Plus® in a 1:1 ratio. All patients will receive drug for 20 days</description>
    <arm_group_label>Sugar pill</arm_group_label>
    <other_name>Ora sweet</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients who have undergone the Fontan procedure (regardless of type of Fontan
             connection or presence or absence of a fenestration)

          -  Age 8.0 to 35.0 years

          -  Stable clinical condition over the last 3 months (i.e. No change in medication,
             treatments, or development of new symptoms)

          -  Ability to perform exercise testing

          -  Consent and assent (as appropriate to participate in the study after receiving
             information concerning procedures, risks, and possible clinical benefits) o Patients
             will be enrolled without regard to gender, race, and ethnicity. All patients meeting
             study eligibility will be approached for consent.

        Exclusion Criteria:

          -  Severe heart failure (New York Heart Association functional class III or IV)

          -  Presence of liver or renal dysfunction based on the latest lab test results

          -  Presence of hearing or visual deficit

          -  Transcutaneous arterial blood oxygen saturation (SaO2) &lt;80% at rest

          -  History of echocardiographic, MRI, or angiographic evidence of Fontan pathway
             obstruction

          -  History of exercise-induced life-threatening arrhythmias or unstable rhythm(i.e.
             atrial flutter)

          -  Known or suspected pregnancy. Females in the reproductive age group will be screened
             for pregnancy using serum beta hCG prior to administering study drug.

          -  Patients on open label sildenafil or tadalafil
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>8 Years</minimum_age>
    <maximum_age>35 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Shaji C. Menon, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Utah</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Linda M. Lambert, APRN</last_name>
    <phone>801 662 5573</phone>
    <email>linda.lambert@imail.org</email>
  </overall_contact>
  <location>
    <facility>
      <name>Primary Childrens Medical Center</name>
      <address>
        <city>Salt lake City</city>
        <state>Utah</state>
        <zip>84113</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Shaji C. Menon, MD</last_name>
      <phone>801-662-5400</phone>
      <email>shaji.menon@imail.org</email>
    </contact>
    <contact_backup>
      <last_name>Linda Lambert, APRN</last_name>
      <phone>801 662 5573</phone>
      <email>linda.lambert@imail.org</email>
    </contact_backup>
    <investigator>
      <last_name>Shaji C. Menon, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>June 2012</verification_date>
  <lastchanged_date>June 6, 2012</lastchanged_date>
  <firstreceived_date>February 4, 2011</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Utah</investigator_affiliation>
    <investigator_full_name>Shaji Menon</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Fontan</keyword>
  <keyword>Tadalafil</keyword>
  <keyword>Exercise performance</keyword>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Tadalafil</mesh_term>
    <mesh_term>Citric Acid</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
